Home / Letter From The Editor / Oct. 11, 2018

Oct. 11, 2018

Oct 11, 2018

All of us are familiar with the value of SGLT-2 Inhibitors, and when we talk to patients we focus on the decreased re-absorption of glucose in the kidney and how that equals a decrease of about 70-100 carbs a day.

However, if you add a GLP-1 analog it is possible that you can get an increase in insulin production and decreased insulin resistance.


Looks like the combination of these 2 classes can address three of the biggest issues for our patients: food choices, insulin production and insulin resistance.

Dave Joffe